Patents by Inventor Ryuta Nishikomori

Ryuta Nishikomori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preventive and therapeutic drug for cartilaginous hyperplasia and method of screening for the same
    Patent number: 9921212
    Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Kyoto University
    Inventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
  • PREVENTIVE AND THERAPEUTIC DRUG FOR CARTILAGINOUS HYPERPLASIA AND METHOD OF SCREENING FOR THE SAME
    Publication number: 20160177406
    Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.
    Type: Application
    Filed: October 9, 2015
    Publication date: June 23, 2016
    Applicant: KYOTO UNIVERSITY
    Inventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike